CN112999336A - Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis - Google Patents

Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis Download PDF

Info

Publication number
CN112999336A
CN112999336A CN202110269039.3A CN202110269039A CN112999336A CN 112999336 A CN112999336 A CN 112999336A CN 202110269039 A CN202110269039 A CN 202110269039A CN 112999336 A CN112999336 A CN 112999336A
Authority
CN
China
Prior art keywords
antioxidase
following
oligosaccharide
steps
treating inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110269039.3A
Other languages
Chinese (zh)
Inventor
简勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lishen Pharmaceutical Co ltd
Original Assignee
Lishen Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lishen Pharmaceutical Co ltd filed Critical Lishen Pharmaceutical Co ltd
Priority to CN202110269039.3A priority Critical patent/CN112999336A/en
Publication of CN112999336A publication Critical patent/CN112999336A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of enteritis treatment, and particularly relates to a preparation method of a medicine containing high-stability novel antioxidase for treating inflammatory enteritis, which comprises the following steps: the method comprises the following steps: placing glucan, fructo-oligosaccharide and galacto-oligosaccharide into a homogenizer for homogenization; step two: adding superoxide dismutase, vitamin C, semen Pruni powder, semen Cassiae powder, Curcuma rhizome, sorbitol, hydroxypropyl methylcellulose, silicon dioxide and magnesium stearate into the homogenized material, and pulverizing; step three: sieving the crushed materials with a 60-mesh sieve and filtering; step four: adding 1% -4% of water into the filtered materials and stirring; step five: the tablet is formed by tabletting in the environment with the temperature of 10-30 ℃ and the humidity of 40-55% RH, the condition that local inflammation is caused by activating various cytokine reactions caused by cell reaction is reduced, and the damage of the intestinal wall is reduced.

Description

Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis
Technical Field
The invention relates to the technical field of enteritis treatment, in particular to a preparation method of a medicine containing high-stability novel antioxidase for treating inflammatory enteritis.
Background
Inflammatory bowel disease is a chronic granulomatous disease of gastrointestinal tract with unknown reasons, is mostly seen in the terminal ileum and adjacent colon, and is characterized by staged or jumping distribution and is full-thickness intestinal wall inflammation. Ulcerative colitis, also known as nonspecific ulcerative colitis, is a chronic inflammatory disease of the rectum and colon of unknown cause. Lesions mainly affect the mucosa and submucosa of the large intestine, and the rectum and distal colon are the most common affected sites, but severe lesions can also affect the whole colon and the terminal ileum. They are generally manifested as diarrhea, abdominal pain, and even some people may have bloody stools. It is currently believed that the pathogenesis of inflammatory bowel disease may be that certain genetic determinants predispose susceptible individuals to disease, stimulate mucosa-associated lymphoid tissues under the action of infectious agents or intestinal luminal antigens, causing an up-regulated T cell response, thereby activating the network of various cytokines, causing local tissue inflammation, which is continuously amplified and sustained, causing damage to the intestinal wall and corresponding clinical manifestations. Glucocorticosteroid (GCS) drugs (prednisone, adrenocortical hormone) and antibiotics are often used for treatment. Poor curative effect, large side effect and easy generation of drug resistance.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The present invention has been made in view of the above and/or other problems occurring in the conventional inflammatory bowel disease drugs.
Therefore, the invention aims to provide a preparation method of a medicine containing high-stability novel antioxidant enzyme for treating inflammatory enteritis, which can effectively supplement the antioxidant enzyme, remove excessive free radicals and effectively reduce oxidative stress and inflammatory reaction.
To solve the above technical problem, according to an aspect of the present invention, the present invention provides the following technical solutions:
the preparation method of the medicine containing the high-stability novel antioxidase for treating the inflammatory enteritis comprises the following steps:
the method comprises the following steps: placing glucan, fructo-oligosaccharide and galacto-oligosaccharide into a homogenizer for homogenization;
step two: adding superoxide dismutase, vitamin C, semen Pruni powder, semen Cassiae powder, Curcuma rhizome, sorbitol, hydroxypropyl methylcellulose, silicon dioxide and magnesium stearate into the homogenized material, and pulverizing;
step three: sieving the crushed materials with a 60-mesh sieve and filtering;
step four: adding 1% -4% of water into the filtered materials and stirring;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
As a preferable scheme of the preparation method of the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis, the medicine comprises the following steps: the medicine is prepared from the following materials in proportion:
260mg of dextran, 200mg of fructo-oligosaccharide, 142mg of galacto-oligosaccharide, 12mg of superoxide dismutase, 2mg of vitamin C, 20mg of bunge cherry seed powder, 20mg of cassia seed powder, 12mg of turmeric, 80mg of sorbitol, 20mg of hydroxypropyl methylcellulose, 16mg of silicon dioxide and 16mg of magnesium stearate.
As a preferable scheme of the preparation method of the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis, the medicine comprises the following steps: the superoxide dismutase is specifically mitochondrial manganese superoxide dismutase.
Compared with the prior art: in the existing medicines, the medicine preparation can not be carried out aiming at oxidative stress and inflammatory reaction, and excessive free radicals can not be effectively eliminated so as to reduce the oxidative stress and the inflammatory reaction.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the present invention will be described in detail with reference to the accompanying drawings and detailed embodiments, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise. Wherein:
FIG. 1 is a schematic flow structure diagram of a preparation method of a medicine containing a high-stability novel antioxidase for treating inflammatory enteritis of the invention.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described herein, and it will be apparent to those of ordinary skill in the art that the present invention may be practiced without departing from the spirit and scope of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Next, the present invention will be described in detail with reference to the drawings, wherein for convenience of illustration, the cross-sectional view of the device structure is not enlarged partially according to the general scale, and the drawings are only examples, which should not limit the scope of the present invention. In addition, the three-dimensional dimensions of length, width and depth should be included in the actual fabrication.
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
The invention provides a preparation method of a medicine containing high-stability novel antioxidase for treating inflammatory enteritis, and referring to fig. 1, the preparation method of the medicine containing high-stability novel antioxidase for treating inflammatory enteritis comprises the following steps:
the method comprises the following steps: placing glucan, fructo-oligosaccharide and galacto-oligosaccharide into a homogenizer for homogenization;
step two: adding superoxide dismutase, vitamin C, semen Pruni powder, semen Cassiae powder, Curcuma rhizome, sorbitol, hydroxypropyl methylcellulose, silicon dioxide and magnesium stearate into the homogenized material, and pulverizing;
step three: sieving the crushed materials with a 60-mesh sieve and filtering;
step four: adding 1% -4% of water into the filtered materials and stirring;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
Referring again to fig. 1, by way of example, the drug is prepared from the following materials:
260mg of dextran, 200mg of fructo-oligosaccharide, 142mg of galacto-oligosaccharide, 12mg of superoxide dismutase, 2mg of vitamin C, 20mg of bunge cherry seed powder, 20mg of cassia seed powder, 12mg of turmeric, 80mg of sorbitol, 20mg of hydroxypropyl methylcellulose, 16mg of silicon dioxide and 16mg of magnesium stearate.
Referring again to fig. 1, the superoxide dismutase is specifically mitochondrial manganese superoxide dismutase which not only inhibits the high-sugar induced increase in collagen synthesis, but also prevents the inhibition of nitric oxide synthase activity by high-sugar.
While the invention has been described above with reference to an embodiment, various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In particular, the various features of the disclosed embodiments of the invention may be used in any combination, provided that no structural conflict exists, and the combinations are not exhaustively described in this specification merely for the sake of brevity and resource conservation. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed, but that the invention will include all embodiments falling within the scope of the appended claims.

Claims (3)

1. The preparation method of the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis is characterized by comprising the following steps: the preparation method of the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis comprises the following steps:
the method comprises the following steps: placing glucan, fructo-oligosaccharide and galacto-oligosaccharide into a homogenizer for homogenization;
step two: adding superoxide dismutase, vitamin C, semen Pruni powder, semen Cassiae powder, Curcuma rhizome, sorbitol, hydroxypropyl methylcellulose, silicon dioxide and magnesium stearate into the homogenized material, and pulverizing;
step three: sieving the crushed materials with a 60-mesh sieve and filtering;
step four: adding 1% -4% of water into the filtered materials and stirring;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
2. The method for preparing the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis according to claim 1, wherein the method comprises the following steps: the medicine is prepared from the following materials in proportion:
260mg of dextran, 200mg of fructo-oligosaccharide, 142mg of galacto-oligosaccharide, 12mg of superoxide dismutase, 2mg of vitamin C, 20mg of bunge cherry seed powder, 20mg of cassia seed powder, 12mg of turmeric, 80mg of sorbitol, 20mg of hydroxypropyl methylcellulose, 16mg of silicon dioxide and 16mg of magnesium stearate.
3. The method for preparing the medicine containing the high-stability novel antioxidase for treating inflammatory enteritis according to claim 2, wherein the method comprises the following steps: the superoxide dismutase is specifically mitochondrial manganese superoxide dismutase.
CN202110269039.3A 2021-03-12 2021-03-12 Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis Pending CN112999336A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110269039.3A CN112999336A (en) 2021-03-12 2021-03-12 Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110269039.3A CN112999336A (en) 2021-03-12 2021-03-12 Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis

Publications (1)

Publication Number Publication Date
CN112999336A true CN112999336A (en) 2021-06-22

Family

ID=76405932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110269039.3A Pending CN112999336A (en) 2021-03-12 2021-03-12 Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis

Country Status (1)

Country Link
CN (1) CN112999336A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159396A1 (en) * 2004-01-20 2005-07-21 Harty Richard F. Compositions and methods of treatment for inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159396A1 (en) * 2004-01-20 2005-07-21 Harty Richard F. Compositions and methods of treatment for inflammatory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TIAN T等: "Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies", OXID MED CELL LONGEV, vol. 2017, pages 216 - 217 *
王啸春;陈小连;赵珂立;徐建雄;: "动物肠道氧化应激及抗氧化剂干预作用研究进展", 中国畜牧杂志, no. 11, pages 73 - 78 *

Similar Documents

Publication Publication Date Title
Singh Psyllium as therapeutic and drug delivery agent
Akolade et al. Encapsulation in chitosan-based polyelectrolyte complexes enhances antidiabetic activity of curcumin
CN102273621B (en) A kind of food of prevention and therapy diabetes or health food
CN101299993A (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
DE202006020331U1 (en) New Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
Li et al. The potential therapeutic effects of hydroxypropyl cellulose on acute murine colitis induced by DSS
WO2015018344A1 (en) Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
CN112999336A (en) Preparation method of medicine containing high-stability novel antioxidase for treating inflammatory enteritis
Li et al. Sialic acid exerts anti-inflammatory effect through inhibiting MAPK-NF-κB/AP-1 pathway and apoptosis in ulcerative colitis
TWI766931B (en) Compositions for use in treating inflammatory bowel diseases
JP2021515802A (en) Rectal mucosa-administered preparation of anemoside B4 and its manufacturing method
EP3741368A1 (en) Capsule for treating ulcerative colitis
KR20210048801A (en) Composition for preventing or treating inflammatory bowel disease comprising sulglycotide as effective component
CN112076249B (en) Application of perilla leaf extract in preparing medicament for treating inflammatory bowel disease
CN107041895A (en) Antrodia camphorata composition for inhibiting renal cancer cell proliferation and improving renal function
CN106474132B (en) Application of the Polaprezinc in preparation treatment or mitigation caused by radiotherapy and chemotherapy intestinal complications and irritable bowel syndrome drug
CN112999234A (en) Application of flavonoid compound and preventive medicine for ulcerative colitis
KR102150548B1 (en) A composition comprising mixture of the herb extract and sulfasalazine for preventing or treating colitis
CN102716128A (en) Pharmaceutical composition for treating asthma
CN113288902A (en) Application of fritillaria cirrhosa in preparation of medicine for preventing and/or treating ulcerative colitis
CN106420697A (en) Polymethoxylated flavone, composition and application of polymethoxylated flavone preparation in preventing or treating diabetes
Liu et al. [Retracted] Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function
CN115414369B (en) Application of cucurbitacin C in preparation of medicines for preventing or treating inflammatory bowel disease
CN105902572A (en) Pharmaceutical composition for treating gastroesophageal reflux diseases and its preparation method and use
CN104095843A (en) Application of arctigenin in preparation of drugs for treatment of digestive tract ulcerative diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination